The Multidisciplinary Pituitary & Skull Base Tumor Center at Memorial Sloan Kettering is involved in a number of clinical trials investigating new medical therapies for patients with Cushing’s disease and acromegaly. These clinical trials give Cushing’s and acromegaly patients access to emerging medications and therapies.

Dr. Geer also follows a large cohort of patients with Cushing’s disease prospectively over time in an effort to understand long-term outcomes for these patients after treatment. She has conducted studies on the effects of Cushing’s on body composition, appetite, and inflammation, and is continuing to investigate changes in adipose tissue on people with Cushing’s before and after treatment. She is also collecting data on mood and quality of life for Cushing’s patients long term. Her prospective Cushing’s cohort is a unique resource for enhancing our understanding of this rare disease, with the aim to improve treatment and outcomes for these patients.

and/or
2 Clinical Trials found
The purpose of this study is to see if the drug pasireotide works well to treat prolactinomas. Prolactinomas are noncancerous pituitary gland tumors that make too much prolactin. Prolactin is a hormone that causes the body to make less estrogen and testosterone (sex hormones).
Cushing's syndrome occurs when the adrenal glands produce too much of the "stress hormone" known as cortisol. This can be caused by a tumor which develops in the pituitary gland and secretes a hormone called adrenocorticotropic hormone (ACTH). Cushing's syndrome can also be caused by an ACTH-secreting tumor elsewhere in the body, or by a tumor in the adrenal glands that makes cortisol.